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Introduction. Adherence to vaccination program for Influenza 
virus is an important issue of Public Health in presence of many 
no-vaccine tendencies. The media event about some deaths, 
occurring after MF59 adjuvanted vaccine administration, has 
characterized the season 2014/15 vaccination program in Italy. 
Aim of the study is vaccination adherence assessment of the cur-
rent season with regards to local health units (LHU) coordina-
tors’s perceptions in Lazio Region (IT). 
Methods. LHU coordinators’s perceptions were collected from a 
questionnaire that was send via email to the all 12 LHU coordina-
tors. The questionnaire was built with 4 questions concerning the 
impression about the vaccination adherence of elderly people in 
the current season. Data from questionnaire was compared with 
the official coverage rate obtained by the Regional Authority. 
Severe adverse events were collected by 1 LHU.
Results. All the 12 LHU coordinators answered to our question-
naire: 7/12 (50%) predicted a coverage rate of at least 50%; 
3/12 (25%) referred a coverage rate around 40-45%; 2/12 (17%) 
predicted a reduction of 5-10% less than the previous season. 
Indeed, a mean 49.1% vaccination coverage in the elderly has 
been reported by the Regional Authority highlighting a reduction 
of 10% less than the 2013/14 season coverage. No severe adverse 
events were observed. 
Discussion. In our survey an important effect of media event 
on anti-flu vaccination program adherence has been evidenced, 
with a failure in communication and joint management of Public 
Health Institutions in Italy about efficacy and safety information 
of flu vaccine.
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Summary
Introduction
Influenza viruses are the etiological agents for flu ill-
ness, an important cause of morbidity and mortality 
worldwide. Flu easily spreads through the population 
and is present year round in the tropics or during win-
ter in the temperate regions. Influenza affects globally 
5-10% of adults and 20-30% of children each year. 
Cases of severe illness are estimated about 3 to 5 mil-
lions, with a mortality around 250 to 500 thousands [1-
4]. In Europe about 10% of the population presents 
symptoms of flu with hundred million hospitalizations 
yearly [5]. In Italy, flu illness affects an average 8% of 
the population [6] and causes more than 8,000 deaths 
per year due to fatal consequences [7]. The clinical 
manifestations of the disease are not typical, and the 
term Influenza-Like-Illness (ILI) is used, which in-
cludes acute self-limited febrile respiratory symptoms 
with muscular pain, asthenia, headache and malaise 
[8]. Case definition of ILI has been recently updated 
from European Centre for Disease Prevention and Con-
trol (ECDC), and it is defined as the sudden onset of 
fever, malaise, headache or myalgia, associated with at 
least one of respiratory symptoms such as cough, sore 
throat or shortness of breath [9]. Course of illness is 
generally mild; however, in some groups (elderly peo-
ple, infants, pregnant women and patients with chronic 
diseases such as diabetes, cardiovascular disorders, 
asthma, BPCO or immunodeficiency) important con-
sequences can be experienced. These complications in-
clude: primary influenza viral pneumonia [10], chronic 
illness exacerbation, secondary bacterial pneumonia, 
sinusitis, otitis media, coinfections with other viral or 
bacterial pathogens [7, 11, 12]. 
To prevent these complications an adequate vaccina-
tion program is important to be planned. The impor-
tance of preventing influenza is mainly for the above-
mentioned groups with an increased risk to develop flu 
complications. In particular, vaccination is important 
in the elderly (people with an age ≥ 65 years), as they 
present a reduced immunological response to microbial 
agents [13, 14]. As influenza viruses are highly mutant, 
vaccine is built from the new circulating viral compo-
nents; consequently, annually vaccine formulation 
made by a global surveillance coordinated by World 
Health Organization (WHO) is required [15]. Once 
vaccine is produced, Public Health Institutions coordi-
nate each year vaccine campaigns for influenza preven-
tion. In Italy, official recommendation for flu preven-
tion program is published each year by Ministero della 
Salute (MdS). Recommendation indicates risk groups 
to whom vaccine has to be offered and the formulations 
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appropriate for each age groups. Vaccine campaign is 
performed from October to December [16]. 
In Italy during 2014/15 flu season, vaccination cam-
paign has been characterized by an important media 
event, which negatively influenced the coverage. Four 
deaths occurred from 1 hour to 5 days after MF59 ad-
juvanted vaccine administration in the period 7-24 No-
vember 2014. Then in November 27, two batches of the 
MF59 adjuvanted vaccine were precautionarily with-
drawn by the Agenzia Italiana del Farmaco (AIFA), 
and exhaustive analyses about their safety were per-
formed [17]. Lazio Region decided to suspend the dis-
tribution of all batches of MF59 adjuvanted vaccine, 
after 2 additional suspected deaths were reported in the 
Region [18, 19].
In December 3, the European Medicine Agency (EMA) 
established the absence of relationship between deaths 
and vaccine administration [20]. To this date, an overall 
19 deaths after MF59 adjuvanted vaccine administration 
were reported to AIFA. In December 24, after Istituto 
Superiore della Sanità (ISS) had verified vaccine safety 
with laboratory tests [21], AIFA removed the block of 
the two batches [22]. After obtaining the positive advice 
of MdS, Lazio Region extended flu vaccination cam-
paign up to January 31, 2015 [23].
In this situation, the emphasis of mass media on report-
ing these news determined an increasing fear about flu 
vaccine and vaccination that spread through the Italian 
population.
Aim of the study is to assess the vaccination adherence 
following the media event in more than 1,200,000 peo-
ple aged ≥ 65 years, resident in Lazio Region, Italy.
Methods
A questionnaire was built with the following four topics: 
flu vaccine distribution, adherence at campaign startup, 
media event effects, coverage projection in ≥ 65 years 
population. In January 26, 2015, the questionnaires were 
sent via email to coordinators of the influenza campaign 
or vaccinations for the 12 local health units (LHU) in 
Lazio. Results of questionnaire were collect via email 
or telephone from January 27 to February 17. Moreover, 
data of severe adverse events after vaccine administra-
tion were collected from one LHU. 
Adverse events were investigated in subjects aged ≥ 
65 years immunized with MF59 adjuvanted vaccine, 
through a 7-days monitoring (namely active surveil-
lance) or through a questionnaire sent to all general prac-
titioners in that LHU (i.e. passive surveillance). 
The distribution of available vaccines in the different 
LHU and the 2013/14 and 2014/15 vaccine coverages 
at the end of November and at the end of the campaign 
were obtained from the Regional Authority. 
Descriptive analyses were made based on the answers 
to 4 questions. The results of these analyses were subse-
quently compared with data of vaccine coverage. 
Results
The responses to the questionnaire were collected from 
12/12 coordinators of LHU. MF59 adjuvanted vaccine 
was available in 12/12 LHU, 10/12 (83%) coordinators 
specified the use in ≥ 65 years people for whom the vac-
cine is licensed.
One or both suspected batches were present in 7/12 
(58%) LHU. 
Almost all the LHU coordinators (11/12) reported a 
startup campaign better or similar to that of the previous 
year; only 1/12 (8%) referred a low initial adherence to 
vaccination program (Fig. 1). 
A personal opinion was asked about the impact of the 
media events on the vaccination campaign as Figure 2. 
Fig. 1. LhU coordinators’ perception on flu vaccination campaign 
startup adherence. 
Fig. 2. LhU coordinators’ judgement about media event impact 
on the 2014/15 flu vaccination campaign.
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In particular: a very negative impact of media event was 
generally perceived by 8/12 (68%) LHU, sometimes de-
scribing a real refusal of flu vaccination with subsequent 
important adherence lowering; 2/12 (16%) specified a 
moderate reduction of the vaccination adherence; 2/12 
(16%) coordinators quantified an hypothetical percent-
age of adherence reduction around 10-15%. 
The LHU coordinators gave their personal projections 
regards to vaccination coverage in the ≥ 65 years popula-
tion: 7/12 (58%) predicted at least 50% coverage; 3/12 
(25%) estimated a coverage less than 50%, included in 
a 40-45% range; 2/12 (17%) answered in terms of cov-
erage reduction, reporting a 5-10% decrease compared 
with the previous influenza vaccine campaign. 
Using these data, a weighted mean 49.7% vaccination 
coverage in people ≥ 65 years was expected, with an es-
timated reduction around 10% compared to the previous 
seasonal coverage data (54.4%), shown in Table I.
Coverage data from Regional Authority showed a 
mean rate among the 12 LHU of 54.4% and 49.1% 
for season 2013/14 and 2014/15 respectively (Tab. I), 
with a decrease in all LHU ranging from 6 to 18%. In 
particular, 3/7 (43%) coordinators of LHU with the 
suspected batches gave an overestimation of effec-
tive coverage in elderly, 4/7 (57%) gave the same or 
a quite lower estimation than the real coverage data. 
Despite that, 4/5 (80%) of the LHU without the sus-
pected batches gave an estimate of reduced coverage 
caused by the media impact similar to the value re-
ported by the Regional Authority. Interestingly, 4/12 
(33%) coordinators had overestimated as well as 4/12 
(33%) had underestimated the coverage reduction, 
without any correlation with the presence of the sus-
pected batches. 
Moreover, a reduced adherence (around 7%) in the first 
2 months of 2014/15 season for elderly has been evi-
denced when compared with the previous seasonal ad-
herence at startup. 
No evidence of severe adverse events were identified 
from both active and passive surveillances. Active sur-
veillance was performed in 95 subjects, of whom 68/95 
received the suspected batches of MF59 adjuvanted vac-
cine. Among general practitioners, 97/456 answered to 
the questionnaire reporting 9,483 subjects immunized 
with MF59 adjuvanted vaccines, of whom 5,916 sub-
jects received the batches under investigation. 
Discussion
Vaccination adherence is an important issue about which 
Public Health Institutions debate for several years. Vac-
cination programs have surely reduced in the last years 
the burden of many infectious diseases with regard to 
incidence, morbidity and mortality. As a consequence 
of this success, general population looks mostly at the 
adverse events to vaccines and underrate their benefi-
cial preventive effects. Due to a supposed low utility, 
a disputable feeling for vaccine is recently organized, 
enhanced and conducted into several no-vaccine tenden-
cies, which strengthen the fear about vaccine utilization 
also with publishing no scientific papers [24]. In par-
ticular, one of the main object of the debate for these 
no-vaccine tendencies is anti-flu vaccine, caused by its 
annual program planning, production and distribution. 
Moreover, general population don’t think that anti-flu 
vaccine is necessary, as influenza is a disease with a 
good prognosis.
Tab. I. Coverage rate of vaccination among elderly in flu season 2013/14 and 2014/15.
LHU
Elderly 
resident 
in Lazio 
2013/14*
Influenza Season 2013/14
Estimated 
LHU 
Projections 
Elderly 
resident 
in Lazio 
2014/15**
Influenza Season 2014/15
Vaccinated
Coverage 
Rate (%)
Coverage 
Rate (%)
Vaccinated
Coverage 
Rate (%)
LhU 1 124163 55207 44.5 45.0 127033 47529 37.4
LhU 2 139543 76522 54.8 50.0 142323 70863 49.8
LhU 3 133991 67743 50.6 46.0 136907 62710 45.8
LhU 4 123031 67609 55.0 50.0 125495 63572 50.7
LhU 5 122856 56880 46.3 46.0 125504 51530 41.1
LhU 6 56564 32354 57.2 45.0 57692 29740 51.5
LhU 7 86500 51279 59.3 50.0 88251 47223 53.5
LhU 8 97343 52874 54.3 53.0 99273 49882 50.2
LhU 9 71759 41299 57.6 50.0 73292 37873 51.7
LhU 10 38539 21904 56.8 55.0 39381 18385 46.7
LhU 11 103017 66567 64.6 59.0 105104 62740 59.7
LhU 12 104187 63357 60.8 50.0 106431 60586 56.9
TOT 1201495 653595 54.4 49.7a 1226686 602633 49.1
LhU: Local health Unit
* data from ISTAT 01/01/2014
** data from ISTAT 01/01/2015, central hypothesis
a Adjusted by ISTAT 01/01/2014
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These considerations cause a low amount of people to 
which vaccine is annually administered, that is often 
lesser than the minimal coverage target built on a 75% 
of people ≥ 65 years by Public Health Institutions [25]. 
This point is well evidenced in Italy, where a mean flu-
vaccine coverage around 60% (range 54.2-68.3%) is ob-
served in the last 10 years. In particular, in Lazio Region 
a progressive low decline in anti-influenza vaccine cov-
erage has been observed in the last years, after a peak of 
74.1% registered in 2006/07 [26]. In 2013/14 season the 
declining trend seemed to get a stop and a lot of work 
had been planned to increase coverage.
In the matter of question, season 2014/15 was character-
ized by an important reduction in terms of adherence to 
vaccination for elderly people, caused by the obsessive 
fear after the media event of suspected deaths related to 
MF59 adjuvanted vaccine administration. The percep-
tion of LHU coordinators is that this fear for flu-vaccine 
was induced and not well managed by the different Ital-
ian Public Health Institutions, as they did not take in 
consideration the media impact for deaths, did not pay 
the right attention to better transmit the vaccine safety 
to general population and, most important, they did not 
act univocally. 
The media event occurred in Italy highlighted the prob-
lem of adverse events management following immuni-
zation. According to WHO recommendations, serious 
adverse events (e.g. deaths) have to be evaluated in 
order to determine the causal or only temporal associa-
tion [27].
In this survey, the LHU coordinator’s perception in 
Lazio Region has been that the vaccine coverage in el-
derly was about 10% less than 2013/14 season, although 
they felt campaign starting better than the previous one. 
This perception has been already confirmed for the re-
duced low adherence of elderly decreasing from 54.4% 
of the previous season to 49.7% of 2014/15 season in all 
LHU, without a correlation between perception and real 
decrease rate. This lack of correlation could be explained 
by the fact that around 99% of people ≥ 65 years resident 
in Lazio has been vaccinated by the general practitioners 
(GP) and not by physician of LHU, with a GP/LHU ratio 
of 122:1. Therefore, LHU coordinators did not receive a 
real-time information about vaccination coverage in the 
elderly.
Moreover, we have pointed out that the media event 
has determined an important flu vaccination coverage 
reduction in the LHU using the suspected batches. The 
decrease was, however, detected also in the LHU not 
having these batches, in those using only a small amount 
of MF59 adjuvanted vaccine and even where both active 
and passive surveillance did not recognize any severe 
adverse event. 
However, this low adherence was already observed at 
startup of vaccination program, because a coverage 
of about 7-9% less than the previous season is report-
ed from official data by Regional Authority. In fact, a 
42.5% mean coverage in elderly has been reported at the 
end of November 2014 in respect to the 46.6% reported 
in November 2013.
These considerations highlight an extreme precaution 
for Italian Public Health Institutions in dealing the ef-
fects of media event [28], in particular for Lazio Region 
with the suspension of all MF59 adjuvanted vaccine 
batches. In fact, after the vaccine was available again the 
Region proposed to prolong the campaign up to the end 
of January; however, there was a delayed final approval 
from MdS and some LHU coordinators referred a late 
official communication press, which took place after 
several general practitioners had already given back to 
LHU all vaccines. 
Conclusions
The media event about the suspected deaths related to 
MF59 adjuvanted vaccine administration has high-
lighted a failure in communication and cooperation of 
Public Health Institutions in Italy. A good management 
of vaccine planning, as well as improving health work-
ers knowledge for vaccine safety and effectiveness, are 
needed to ensure the right level of vaccination coverage 
and increase the acceptance of immunization by the tar-
get population.
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